glp-1 bacteria Not Working? Your Gut Microbiome May Be the Reason 🧬 Did you know your

Understanding why your GLP-1 therapy may not be delivering anticipated results is essential for working with your healthcare team to optimise treatment outcomes and achieve your therapeutic goals

doi: 10.1056/NEJMoa1515920 7 NealBPerkovicVMahaffeyKWde ZeeuwDFulcherGEronduNet al

This latest research suggests it can also be a valuable preventative treatment for people at high risk of heart conditions.

Meta-analyses show GLP-1 receptor agonists can reduce inflammatory biomarkers, including CRP , with improvements also reported across other inflammatory and oxidative stress measures in studied populations., Why this matters: Lowering metabolic inflammation overlaps with meaningful improvements in long-term health risk pathways, including cardiometabolic risk and metabolic organ stresseven if patients dont feel inflammation improving day to day., 2) They Improve Liver Inflammation ( NAFLD / MASH ) Semaglutide and tirzepatide show some of the strongest evidence for metabolically driven liver disease